BACKGROUND AND PURPOSE: Quality of life (QOL) was measured prospectively in a dose escalation study of twice daily hyperfractionated, accelerated radiotherapy for locally advanced head and neck cancer (HNC). MATERIALS AND METHODS: Patients with squamous cell HNC (TNM stage III/IV larynx or pharynx, or hypopharynx any stage) received 40 fractions of twice daily RT at 3 dose levels: (L1) 60Gy, 1.5Gy/fraction; (L2) 62Gy, 1.55Gy/fraction; and (L3) 64Gy, 1.6Gy/fraction. QOL was measured on the FACT-H&N at baseline, 6 and 12 months. RESULTS: Mean QOL scores were: baseline 104, 6 months 108, 12 months 112. At all time points, QOL scores were lower in patients with more advanced T-category. A mixed-model analysis of determinants of QOL showed no dose effect among L1 (n=22), L2 (n=26) or L3 (n=123). QOL improved significantly with time from diagnosis, however post-treatment QOL was lower and improved more slowly in patients who had feeding tubes. CONCLUSIONS: Post-RT QOL improved from baseline by a statistically and clinically significant amount. Hyperfractionated, accelerated RT provides favorable QOL outcomes, and is a viable alternative to chemoradiation for patients with locally advanced HNC.
BACKGROUND AND PURPOSE: Quality of life (QOL) was measured prospectively in a dose escalation study of twice daily hyperfractionated, accelerated radiotherapy for locally advanced head and neck cancer (HNC). MATERIALS AND METHODS:Patients with squamous cell HNC (TNM stage III/IV larynx or pharynx, or hypopharynx any stage) received 40 fractions of twice daily RT at 3 dose levels: (L1) 60Gy, 1.5Gy/fraction; (L2) 62Gy, 1.55Gy/fraction; and (L3) 64Gy, 1.6Gy/fraction. QOL was measured on the FACT-H&N at baseline, 6 and 12 months. RESULTS: Mean QOL scores were: baseline 104, 6 months 108, 12 months 112. At all time points, QOL scores were lower in patients with more advanced T-category. A mixed-model analysis of determinants of QOL showed no dose effect among L1 (n=22), L2 (n=26) or L3 (n=123). QOL improved significantly with time from diagnosis, however post-treatment QOL was lower and improved more slowly in patients who had feeding tubes. CONCLUSIONS: Post-RT QOL improved from baseline by a statistically and clinically significant amount. Hyperfractionated, accelerated RT provides favorable QOL outcomes, and is a viable alternative to chemoradiation for patients with locally advanced HNC.
Authors: L Miszczyk; B Maciejewski; A Tukiendorf; G Woźniak; B Jochymek; A Gawryszuk; M Szweda Journal: Br J Radiol Date: 2014-07-16 Impact factor: 3.039
Authors: Christiaan Seimeon Michael Stevens; Betty Lemon; Gina A Lockwood; John N Waldron; Andrea Bezjak; Jolie Ringash Journal: Support Care Cancer Date: 2010-06-24 Impact factor: 3.603
Authors: Colin Lavigne; Harold Lau; George Francis; S Nicole Culos-Reed; Guillaume Y Millet; Rosie Twomey Journal: Eur J Appl Physiol Date: 2020-04-06 Impact factor: 3.078
Authors: Bena Cartmill; Petrea Cornwell; Elizabeth Ward; Wendy Davidson; Sandro Porceddu Journal: Support Care Cancer Date: 2011-11-15 Impact factor: 3.603
Authors: Talya Salz; Jamie S Ostroff; Chandylen L Nightingale; Thomas M Atkinson; Eleanor C Davidson; Sankeerth R Jinna; Anuja Kriplani; Glenn J Lesser; Kathleen A Lynch; Deborah K Mayer; Kevin C Oeffinger; Sujata Patil; Andrew L Salner; Kathryn E Weaver Journal: Contemp Clin Trials Date: 2021-05-21 Impact factor: 2.261
Authors: Houda Bahig; Brandon G Gunn; Adam S Garden; Rong Ye; Kate Hutcheson; David I Rosenthal; Jack Phan; Clifton D Fuller; William H Morrison; Jay Paul Reddy; Sweet Ping Ng; Neil D Gross; Erich M Sturgis; Renata Ferrarotto; Maura Gillison; Steven J Frank Journal: Int J Part Ther Date: 2021-06-25
Authors: Mohamad R Issa; Stuart E Samuels; Emily Bellile; Firas L Shalabi; Avraham Eisbruch; Gregory Wolf Journal: Cancers (Basel) Date: 2015-11-10 Impact factor: 6.639